Cell Therapeutics Inc  (CTIC) Trade Now »     Rate CTIC  -  Discuss CTIC  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

CTIC Analysis & Videos »


CTIC: Bull or Bear?

Short Cell Therapeutics, Inc (CTIC) CTIC

N/A

+22.00% in 40 days (closed on 11/05/09) Insiders are selling Revenues are down EPS are down CTIC underperform compare with the market last 3m Make Money -  http://www.money-top10.com/ Investments - http://www.stockpicksexpert.com/ Cell Therapeutics, Inc., a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a phase III trial product, for non-Hodgkin?s lymphoma; Brostallicin, which is in first-line Phase II study for the treatment of sarcoma; and OPAXIO, a chemotherapeuti... Continue reading »

By  stockexpert   (+3.71%  risk: conservative)  09/26/09

4 comments

FDA Calendar Updates: Cell Therapeutics (NASDAQ:CTIC) CTIC

73%

-38.67% in 92 days (closed on 10/29/09)   <> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of 285 entries as of 7/29/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the F... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  07/29/09

Comment

Extreme FDA Calendar Trades: 21 Stocks Under $5 CTIC

73%

+2.74% in 9 days (closed on 07/29/09) <> Below are extreme trades among 21 companies with stock prices under $5 from the <font> BioMedReports.com FDA Calendar </font> , which includes 264 entries as of 7/20/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submi... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  07/20/09

Comment

Access Pharma (OTC:ACCP): Deep Pipeline, Shallow Valuation CTIC

73%

+5.80% in 6 days (closed on 07/20/09) <> Access Pharma (OTC:ACCP)(ACCP.OB) is an emerging bio-pharmaceutical company which is focusing on the development of a late-stage, diversified oncology pipeline in addition to a treatment for a common side effect of some cancer treatments known as mucositis (painful sores in the mouth and GI mucosal lining) which has already received FDA 510(k) marketing clearance and European CE Mark approval. On 7/13/09, Access announced that it would be among the LifeTech Capital Group companies presenting at Jesup & Lamont’s 2009 Growth Stock & National Sales Conference to be held at the Waldorf Astoria<><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  07/14/09

Comment

FDA Extreme Trades: 16 Stocks Under $5 CTIC

73%

-25.41% in 17 days (closed on 07/14/09) <> Below are FDA extreme trades among 16 companies with stock prices under $5 from the <font> BioMedReports.com FDA Calendar </font> (database includes 225 entries as of 6/27/09) which have pending FDA decisions for either new drug products, biological agents, medical devices, or diagnostic tests that may have a major impact on each of the underlying stock prices. A high risk/reward trading approach to consider for speculative traders is investing a small amount of money that you can afford to lose in a basket of stocks included in <> <font> Extreme FDA and Clinical Trial Calendar Trade... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  06/27/09

Comment

Bullish on CTIC ... CTIC

N/A

-20.00% in 38 days (closed on 08/03/09) <font> http://news.moneycentral.msn.com/ticker/article.aspx?Feed=AP&... </font>   <font> http://news.moneycentral.msn.com/ticker/article.aspx?Feed=Bco... </font>   Continue reading »

By  legan   (+2.47%  risk: conservative)  06/26/09

Comment

Lixte Biotech (OTC:LIXT): Key 2H09 Catalysts Await CTIC

73%

+31.21% in 4 days (closed on 06/27/09) <> Since I first wrote about Lixte Biotech (OTC:LIXT) at <font> BioMedReports.com in early April </font> , the Company has provided an update on its development-stage cancer drug discovery operations as part of a SEC 10Q filing in mid-May for 1Q09. LIXT.OB was originally founded as a diagnostics company in 2005 evaluating biomarkers (indicators of disease at the molecular level), but has shifted its focus to cancer drug discovery research that is primarily focused on the development of compounds for malignancies with few effective treatment options – such as certain types of brain cancer<><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  06/23/09

Comment

Access Pharma: A Cancer Biotech Call Option Trade CTIC

73%

+13.72% in 27 days (closed on 06/23/09) <> The cancer biotech space has attracted the interest of investors, traders, and diversified healthcare giants this year with Johnson & Johnson (NYSE: JNJ) announcing a $1B cash tender offer for Cougar Biotech (NASDAQ: CGRB) last week and Roche's (VTX: ROG) (OTC: RHHBY) mega-deal to acquire full control of Genentech earlier this year. In addition, positive clinical trial results for Dendreon's (NASDAQ: DNDN) Provenge and stock price turnarounds from the brink of zero at Cell Therapeutics (NASDAQ: CTIC) have fueled interest in the small and micro-cap cancer bio-pharma space among investors an... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  05/27/09

Comment

Clinical Trial Updates: Cancer Drugs in Focus as ASCO Approaches CTIC

73%

+4.19% in 10 days (closed on 05/27/09) <> Below is a summary of updates to the <font> BioMedReports.com </font> database of over 200 entries included in the <font> FDA and Clinical Trial Calendars </font> . The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA fo... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  05/17/09

Comment

Cell Therapeutics Sells $20M in Stock, Warrants CTIC

73%

-26.54% in 6 days (closed on 05/17/09)   After the market close, Cell Therapeutics (NASDAQ:CTIC) announced the sale of $20M of its common stock at $1.25 per share along with warrant coverage to a single institutional investor. CTIC plans to use $17.8M in cash on hand and/or raised through this sale to pay for its anticipated 'Modified Dutch Auction' tender offer to retire between $83.2-89.2 million of convertible debt within an expected range of $250-300 per $1,000 par value of the bonds.   <> The sale announced today includes 30% warrant coverage on the $20M offering price with an exercise price of $1.40 pe... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  05/11/09

Comment

Cell Therapeutics: Turnaround Remains On Track CTIC

73%

+51.40% in 4 days (closed on 05/11/09) The dramatic turnaround from lows of a nickel per share ealier this year at cancer biotech Cell Therapeutics (NASDAQ:CTIC) remains on track as the Company announced its 1Q09 results today, which included a 76% reduction of net loss and expected completion of the pixantrone NDA filing this June. Earlier this week, CTIC announced that pixantrone was made available through a compassionate use program in Europe on a named-patient basis for use in the treatment of aggressive non-Hodgkin's lymphoma (NHL) that has either relapsed or is refractory to standard treatment options.   <> CTIC a... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  05/07/09

Comment

Cell Therapeutics Inc rebounds after offer rejection CTIC

61%

-1.94% in 6 days (closed on 04/19/07) Background: Cell Therapeutics, Inc. engages in the development, acquisition, and commercialization of treatments for cancer. The company offers XYOTAX, a Phase III clinical trial chemotherapeutic agent, which links anti cancer agent called paclitaxel to a polyglutamate polymer for the treatment of non-small cell lung cancer and ovarian cancers in females. finance.yahoo.com/q/pr Recent News: DOR rejects buyout offer April 12, 2007: DOR BioPharma said its board has rejected a buyout offer from Cell Therapeutics as being "inadequate for shareholders." <>biz.yahoo.com/bizj/... Continue reading »

By  Aircarp   (+11.98%  risk: aggressive)  04/13/07

Comment

People Bullish on CTIC

zerofootprint3@hotmail.com Analyst N/A 2 days ago	mbmalone Analyst N/A 22 days ago	mulder Analyst N/A 23 days ago
hbnsprgr1 Analyst N/A 24 days ago	chlim Analyst N/A about 1 mo ago

People Bearish on CTIC

Mike Havrilla Principal 73% 24 days ago	myjini Analyst N/A about 1 mo ago	tired_ant Analyst N/A about 1 mo ago
johny.nguyen Analyst N/A about 1 mo ago	ancrimat Analyst N/A about 1 mo ago

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.